百奥泰：达尔扑拜单抗注射液（BAT4406F）上市许可申请获得受理

Core Viewpoint - The company has received a notice of acceptance from the National Medical Products Administration for the marketing authorization application of its investigational drug, BAT4406F, which is intended for the treatment of adult patients with neuromyelitis optica spectrum disorder (NMOSD) who are positive for aquaporin-4 (AQP4) antibodies [1] Group 1 - The drug BAT4406F is specifically designed for NMOSD patients [1] - The approval from the regulatory authority marks a significant step in the drug's development process [1] - The indication of the drug targets a specific patient population, enhancing its market potential [1]